|
CA1271477A
(en)
|
1983-11-18 |
1990-07-10 |
John F. Gerster |
1h-imidazo[4,5-c]quinolin-4-amines
|
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
|
US5567610A
(en)
|
1986-09-04 |
1996-10-22 |
Bioinvent International Ab |
Method of producing human monoclonal antibodies and kit therefor
|
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Acylhydrazone derivatives of anthracycline and methods for their preparation
|
|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
|
US6399754B1
(en)
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
|
US5229275A
(en)
|
1990-04-26 |
1993-07-20 |
Akzo N.V. |
In-vitro method for producing antigen-specific human monoclonal antibodies
|
|
US5567588A
(en)
|
1990-06-11 |
1996-10-22 |
University Research Corporation |
Systematic evolution of ligands by exponential enrichment: Solution SELEX
|
|
US5660985A
(en)
|
1990-06-11 |
1997-08-26 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands containing modified nucleotides
|
|
US5789163A
(en)
|
1990-06-11 |
1998-08-04 |
Nexstar Pharmaceuticals, Inc. |
Enzyme linked oligonucleotide assays (ELONAS)
|
|
US6001577A
(en)
|
1998-06-08 |
1999-12-14 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
|
|
ES2259800T3
(es)
|
1990-06-11 |
2006-10-16 |
Gilead Sciences, Inc. |
Procedimientos de uso de ligandos de acido nucleico.
|
|
US6716580B2
(en)
|
1990-06-11 |
2004-04-06 |
Somalogic, Inc. |
Method for the automated generation of nucleic acid ligands
|
|
US5853984A
(en)
|
1990-06-11 |
1998-12-29 |
Nexstar Pharmaceuticals, Inc. |
Use of nucleic acid ligands in flow cytometry
|
|
US5874218A
(en)
|
1990-06-11 |
1999-02-23 |
Nexstar Pharmaceuticals, Inc. |
Method for detecting a target compound in a substance using a nucleic acid ligand
|
|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
|
US5763177A
(en)
|
1990-06-11 |
1998-06-09 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
|
|
US5496938A
(en)
|
1990-06-11 |
1996-03-05 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligands to HIV-RT and HIV-1 rev
|
|
US6280932B1
(en)
|
1990-06-11 |
2001-08-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands to lectins
|
|
US6465189B1
(en)
|
1990-06-11 |
2002-10-15 |
Gilead Sciences, Inc. |
Systematic evolution of ligands by exponential enrichment: blended selex
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
FI941572A7
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
|
|
US5226575A
(en)
|
1991-11-21 |
1993-07-13 |
Scott Faust |
Pneumatic mortar dispenser with flex release
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
CA2372813A1
(en)
|
1992-02-06 |
1993-08-19 |
L.L. Houston |
Biosynthetic binding protein for cancer marker
|
|
US6608201B2
(en)
|
1992-08-28 |
2003-08-19 |
3M Innovative Properties Company |
Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
|
US6458539B1
(en)
|
1993-09-17 |
2002-10-01 |
Somalogic, Inc. |
Photoselection of nucleic acid ligands
|
|
US5798340A
(en)
|
1993-09-17 |
1998-08-25 |
Gilead Sciences, Inc. |
Nucleotide analogs
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5482936A
(en)
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5843732A
(en)
|
1995-06-06 |
1998-12-01 |
Nexstar Pharmaceuticals, Inc. |
Method and apparatus for determining consensus secondary structures for nucleic acid sequences
|
|
DK0871490T3
(da)
|
1995-12-22 |
2003-07-07 |
Bristol Myers Squibb Co |
Forgrenede hydrazonlinkere
|
|
US5922695A
(en)
|
1996-07-26 |
1999-07-13 |
Gilead Sciences, Inc. |
Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
|
|
DE59708838D1
(de)
|
1996-08-30 |
2003-01-09 |
Jens Peter Fuerste |
Spiegelselektion und spiegelevolution von nucleinsäuren
|
|
US6127533A
(en)
|
1997-02-14 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
2'-O-aminooxy-modified oligonucleotides
|
|
UA67760C2
(uk)
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
|
US6242246B1
(en)
|
1997-12-15 |
2001-06-05 |
Somalogic, Inc. |
Nucleic acid ligand diagnostic Biochip
|
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
|
US6403779B1
(en)
|
1999-01-08 |
2002-06-11 |
Isis Pharmaceuticals, Inc. |
Regioselective synthesis of 2′-O-modified nucleosides
|
|
US20030054360A1
(en)
|
1999-01-19 |
2003-03-20 |
Larry Gold |
Method and apparatus for the automated generation of nucleic acid ligands
|
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
|
BR0012196A
(pt)
|
1999-06-25 |
2002-03-19 |
Genentech Inc |
Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
|
|
US6506887B1
(en)
|
1999-07-29 |
2003-01-14 |
Somalogic, Incorporated |
Conditional-selex
|
|
US6635677B2
(en)
|
1999-08-13 |
2003-10-21 |
Case Western Reserve University |
Methoxyamine combinations in the treatment of cancer
|
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
|
US20050020525A1
(en)
|
2002-02-20 |
2005-01-27 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US20050032733A1
(en)
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
DE20014503U1
(de)
|
2000-08-22 |
2001-01-11 |
Siemens AG, 80333 München |
Fertigungsstraßenabschnitt
|
|
US6376190B1
(en)
|
2000-09-22 |
2002-04-23 |
Somalogic, Inc. |
Modified SELEX processes without purified protein
|
|
EP1850850A4
(en)
|
2000-12-08 |
2011-06-15 |
3M Innovative Properties Co |
COMPOSITIONS AND METHOD FOR TARGETED ADMINISTRATION OF IMMUNE RESPONSE MODIFICATORS
|
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
UA74852C2
(en)
|
2000-12-08 |
2006-02-15 |
3M Innovative Properties Co |
Urea-substituted imidazoquinoline ethers
|
|
US6664264B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
|
UA74593C2
(en)
|
2000-12-08 |
2006-01-16 |
3M Innovative Properties Co |
Substituted imidazopyridines
|
|
US20030175950A1
(en)
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
|
EP1264603B8
(en)
|
2001-06-10 |
2010-03-03 |
Noxxon Pharma AG |
Use of L-polynucleotides for in vivo imaging
|
|
AU2775402A
(en)
|
2001-06-29 |
2003-01-02 |
Medimolecular Pty Ltd |
Nucleic acid ligands to complex targets
|
|
US20030139364A1
(en)
|
2001-10-12 |
2003-07-24 |
University Of Iowa Research Foundation |
Methods and products for enhancing immune responses using imidazoquinoline compounds
|
|
EP1455700A4
(en)
|
2001-11-16 |
2007-02-14 |
3M Innovative Properties Co |
METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS
|
|
AP2004003069A0
(en)
|
2001-11-27 |
2004-06-30 |
Anadys Pharmaceuticals Inc |
3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
|
|
WO2003057145A2
(en)
|
2001-12-31 |
2003-07-17 |
Guilford Pharmaceuticals Inc. |
SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
AU2003276131A1
(en)
|
2002-06-18 |
2003-12-31 |
Epigenesis Pharmaceuticals, Inc. |
A dry powder oligonucleotide formulation, preparation and its uses
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
DK1545613T3
(da)
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
|
EP1413316A1
(en)
|
2002-09-27 |
2004-04-28 |
Bruno Robert |
Bifunctional conjugates or fusion proteins
|
|
CA2510375A1
(en)
|
2002-12-20 |
2004-07-15 |
3M Innovative Properties Company |
Aryl / hetaryl substituted imidazoquinolines
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US20050036951A1
(en)
|
2003-01-09 |
2005-02-17 |
Arizeke Pharmaceuticals, Inc. |
Methods of treating lung diseases
|
|
US9259459B2
(en)
|
2003-01-31 |
2016-02-16 |
Celldex Therapeutics Inc. |
Antibody vaccine conjugates and uses therefor
|
|
JP2006517974A
(ja)
|
2003-02-13 |
2006-08-03 |
スリーエム イノベイティブ プロパティズ カンパニー |
Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
|
|
JP5356648B2
(ja)
|
2003-02-20 |
2013-12-04 |
シアトル ジェネティックス， インコーポレイテッド |
抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
|
|
JP2007504232A
(ja)
|
2003-09-05 |
2007-03-01 |
アナディス ファーマシューティカルズ インク |
Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
|
|
KR20060120069A
(ko)
|
2003-10-03 |
2006-11-24 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
피라졸로피리딘 및 그의 유사체
|
|
AR046046A1
(es)
|
2003-10-03 |
2005-11-23 |
3M Innovative Properties Co |
Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
|
|
RU2426734C2
(ru)
|
2003-10-03 |
2011-08-20 |
Зм Инновейтив Пропертиз Компани |
Пиразолопиридины и их аналоги
|
|
CA2542099A1
(en)
|
2003-10-11 |
2005-04-21 |
Inex Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
|
ITMI20032121A1
(it)
|
2003-11-04 |
2005-05-05 |
Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm |
Procedimento per la preparazione di imiquimod e suoi intermedi
|
|
EP2478912B1
(en)
*
|
2003-11-06 |
2016-08-31 |
Seattle Genetics, Inc. |
Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
|
|
US20050239735A1
(en)
|
2003-12-30 |
2005-10-27 |
3M Innovative Properties Company |
Enhancement of immune responses
|
|
US8012964B2
(en)
|
2004-03-26 |
2011-09-06 |
Dainippon Sumitomo Pharma Co., Ltd. |
9-substituted 8-oxoadenine compound
|
|
EP1776105A2
(en)
*
|
2004-07-18 |
2007-04-25 |
Coley Pharmaceutical Group, Ltd |
Methods and compositions for inducing innate immune responses
|
|
DK1791565T3
(en)
*
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
|
CA2586913A1
(en)
|
2004-11-09 |
2006-05-18 |
University Of Southern California |
Targeted innate immunity
|
|
PL1830876T3
(pl)
*
|
2004-12-30 |
2015-09-30 |
Meda Ab |
Zastosowanie imikwimodu do leczenia przerzutów do skóry wywodzących się od guza stanowiącego raka piersi
|
|
CN101128431B
(zh)
|
2005-02-24 |
2011-05-25 |
詹森药业有限公司 |
作为钾离子通道打开剂的喹啉衍生物
|
|
CN101155932A
(zh)
|
2005-04-14 |
2008-04-02 |
默克专利有限公司 |
基于在肿瘤组织中增加的egfr基因拷贝数的抗egfr抗体治疗
|
|
JP5122441B2
(ja)
|
2005-04-19 |
2013-01-16 |
シアトル ジェネティックス， インコーポレイテッド |
ヒト化抗ｃｄ７０結合剤およびその使用
|
|
CN103285392A
(zh)
|
2005-04-26 |
2013-09-11 |
卫材R&D管理株式会社 |
用于癌症免疫疗法的组合物和其用途
|
|
KR101418369B1
(ko)
|
2005-05-04 |
2014-07-24 |
녹손 파르마 아게 |
스피에겔머들의 신규 용도
|
|
DK2439273T3
(da)
*
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
WO2007008848A2
(en)
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
|
|
TW201402124A
(zh)
|
2005-08-19 |
2014-01-16 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
|
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
|
|
EP1928912A4
(en)
|
2005-09-07 |
2010-02-24 |
Medimmune Inc |
EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS
|
|
ZA200803029B
(en)
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
|
EP2354163A3
(en)
*
|
2005-09-26 |
2013-04-24 |
Medarex, Inc. |
Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies
|
|
EP1988896A4
(en)
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
CONJUGATES TO MODIFY IMMUNE REACTIONS
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
US20080031887A1
(en)
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
|
US8138172B2
(en)
|
2006-07-05 |
2012-03-20 |
Astrazeneca Ab |
8-oxoadenine derivatives acting as modulators of TLR7
|
|
BRPI0717638A2
(pt)
|
2006-10-27 |
2013-11-12 |
Genentech Inc |
Anticorpors e imunoconjugados e usos para os mesmos
|
|
MY148217A
(en)
|
2006-12-21 |
2013-03-29 |
Hoffmann La Roche |
Polymorphs of a mglur5 receptor antagonist
|
|
US20080149123A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
|
US20080261913A1
(en)
|
2006-12-28 |
2008-10-23 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of liver disorders
|
|
TWI422594B
(zh)
|
2007-02-02 |
2014-01-11 |
Baylor Res Inst |
經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
|
|
CN101790380B
(zh)
|
2007-02-07 |
2013-07-10 |
加利福尼亚大学董事会 |
合成tlr激动剂的缀合物及其应用
|
|
JP5394246B2
(ja)
*
|
2007-03-30 |
2014-01-22 |
ジェネンテック， インコーポレイテッド |
抗体及びイムノコンジュゲートとこれらの使用方法
|
|
HRP20120895T1
(hr)
|
2007-05-08 |
2012-11-30 |
Astrazeneca Ab |
Imidazokinolini sa imuno-modulacijskim svojstvima
|
|
RU2010107199A
(ru)
|
2007-07-31 |
2011-09-10 |
Дзе Джонс Хопкинс Юниверсити (Us) |
Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
|
|
US20090304719A1
(en)
|
2007-08-22 |
2009-12-10 |
Patrick Daugherty |
Activatable binding polypeptides and methods of identification and use thereof
|
|
EP2436376B1
(en)
|
2007-09-28 |
2014-07-09 |
BIND Therapeutics, Inc. |
Cancer cell targeting using nanoparticles
|
|
AU2008347400B2
(en)
|
2008-01-15 |
2014-12-11 |
Meda Ab |
Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives
|
|
CA2713137C
(en)
|
2008-01-25 |
2017-10-24 |
Hadasit Medical Research Services And Development Ltd. |
Targeting of innate immune response to tumor site
|
|
EA201001264A1
(ru)
*
|
2008-02-07 |
2011-04-29 |
Дзе Регентс Оф Дзе Юниверсити Оф Калифорния |
Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
|
|
DK2644194T3
(en)
|
2008-03-18 |
2017-07-03 |
Genentech Inc |
Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
|
|
EP2316032A1
(en)
|
2008-08-20 |
2011-05-04 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
US8895702B2
(en)
|
2008-12-08 |
2014-11-25 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
|
|
RS53347B
(sr)
|
2008-12-09 |
2014-10-31 |
Gilead Sciences, Inc. |
Modulatori toll-sličnih receptora
|
|
RU2636046C2
(ru)
|
2009-01-12 |
2017-11-17 |
Сайтомкс Терапьютикс, Инк |
Композиции модифицированных антител, способы их получения и применения
|
|
EP2427485B1
(en)
|
2009-05-07 |
2016-12-07 |
ImmunoCellular Therapeutics, Ltd. |
Cd133 epitopes
|
|
WO2010132622A2
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of California |
Anticd20-cpg conjugates and methods of treating b cell malignancies
|
|
US20110077263A1
(en)
|
2009-09-29 |
2011-03-31 |
University Of Southern California |
Methods and Compositions of Toll-Like Receptor (TLR) Agonists
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
WO2011084726A1
(en)
|
2009-12-21 |
2011-07-14 |
3M Innovative Properties Company |
BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
|
|
WO2011084725A1
(en)
|
2009-12-21 |
2011-07-14 |
3M Innovative Properties Company |
4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
|
|
EA201690310A1
(ru)
|
2010-04-13 |
2016-12-30 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающие cd27 человека, и их применение
|
|
CA2798739A1
(en)
|
2010-05-26 |
2011-12-01 |
Selecta Biosciences, Inc. |
Nanocarrier compositions with uncoupled adjuvant
|
|
KR20130108295A
(ko)
|
2010-08-13 |
2013-10-02 |
베일러 리서치 인스티튜트 |
항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
|
|
EP3195868A3
(en)
|
2010-10-01 |
2017-08-02 |
VentiRx Pharmaceuticals, Inc. |
Therapeutic use of a tlr agonist and combination therapy
|
|
CN103476407A
(zh)
*
|
2010-12-09 |
2013-12-25 |
霍夫曼-拉罗奇有限公司 |
用帕利他赛和曲妥珠单抗-mcc-dm1治疗her2阳性癌症
|
|
DK2663555T3
(en)
|
2011-01-12 |
2017-03-27 |
Ventirx Pharmaceuticals Inc |
SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
|
|
WO2012104344A1
(en)
|
2011-02-01 |
2012-08-09 |
Genmab A/S |
Human antibodies and antibody-drug conjugates against cd74
|
|
TW201247706A
(en)
|
2011-03-08 |
2012-12-01 |
Baylor Res Inst |
Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
AU2012244549B2
(en)
|
2011-04-21 |
2017-04-20 |
Origenis Gmbh |
Heterocyclic compounds as kinase inhibitors
|
|
UY34032A
(es)
|
2011-04-21 |
2012-11-30 |
Origenis Gmbh |
Nuevos inhibidores de quinasa
|
|
US8728486B2
(en)
|
2011-05-18 |
2014-05-20 |
University Of Kansas |
Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
|
|
CA2840018C
(en)
|
2011-07-24 |
2019-07-16 |
Curetech Ltd. |
Variants of humanized immunomodulatory monoclonal antibodies
|
|
MX368257B
(es)
|
2011-08-01 |
2019-09-26 |
Genentech Inc |
Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
|
|
CN103748084B
(zh)
|
2011-08-11 |
2016-07-06 |
亨斯迈先进材料美国有限责任公司 |
制备苯并噁嗪化合物的方法
|
|
EP2758080B1
(en)
|
2011-09-19 |
2018-03-07 |
The Johns Hopkins University |
Cancer immunotherapy
|
|
WO2013063277A1
(en)
|
2011-10-25 |
2013-05-02 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
|
AU2012334825B2
(en)
|
2011-11-09 |
2017-08-24 |
Ascend Biopharmaceuticals Ltd |
Immunomodulatory conjugates
|
|
WO2013166110A1
(en)
*
|
2012-05-02 |
2013-11-07 |
Yale University |
Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
CN111499755A
(zh)
|
2012-08-03 |
2020-08-07 |
丹娜法伯癌症研究院 |
抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
|
|
TWI606063B
(zh)
|
2012-08-23 |
2017-11-21 |
艾澤西公司 |
結合至１５８ｐ１ｄ７蛋白之抗體藥物結合物（ａｄｃ）
|
|
WO2014060113A1
(en)
|
2012-10-19 |
2014-04-24 |
Origenis Gmbh |
Novel kinase inhibitors
|
|
WO2014060112A1
(en)
|
2012-10-19 |
2014-04-24 |
Origenis Gmbh |
Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
|
|
EP2787005A1
(en)
|
2013-04-02 |
2014-10-08 |
Activartis Biotech GmbH |
Targeted cancer immune therapy
|
|
KR20230076867A
(ko)
|
2013-12-20 |
2023-05-31 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
|
DK3092256T3
(da)
|
2014-01-10 |
2022-06-20 |
Birdie Biopharmaceuticals Inc |
Forbindelser og sammensætninger til immunterapi
|
|
WO2015200728A1
(en)
|
2014-06-25 |
2015-12-30 |
Selecta Biosciences, Inc. |
Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
|
|
CN121243402A
(zh)
|
2014-07-09 |
2026-01-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1组合
|
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
CN105732635A
(zh)
|
2014-12-29 |
2016-07-06 |
南京明德新药研发股份有限公司 |
一类Toll样受体7激动剂
|
|
JP6141568B1
(ja)
|
2015-09-01 |
2017-06-07 |
大鵬薬品工業株式会社 |
新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩
|
|
US10821127B2
(en)
|
2015-11-09 |
2020-11-03 |
Shaperon Inc. |
Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
CA3067268A1
(en)
|
2017-06-23 |
2018-12-27 |
Birdie Biopharmaceuticals, Inc. |
Crystalline resiquimod monosulfate anhydrate and its preparation and uses
|
|
AU2019335366A1
(en)
|
2018-09-07 |
2021-03-25 |
Birdie Biopharmaceuticals, Inc. |
Imidazoquinoline compounds and uses thereof
|
|
CA3125133A1
(en)
|
2018-12-26 |
2020-07-02 |
Birdie Biopharmaceuticals, Inc. |
Immune modulatory combinations and methods for treating cancers
|
|
US20220175762A1
(en)
|
2019-03-15 |
2022-06-09 |
Birdie Biopharmaceuticals, Inc. |
Immune modulatory compositions and methods for treating cancers
|
|
AU2021332350A1
(en)
|
2020-08-26 |
2023-03-16 |
Birdie Pharmaceuticals, Inc. |
Cancer treatment with TLR agonist
|